177Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice

Background CD37 is an internalizing B-cell antigen expressed on Non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia cells (CLL). The anti-CD37 monoclonal antibody HH1 was conjugated to the bifunctional chelator p-SCN-Bn-DOTA and labelled with the beta-particle emitting radionuclide 177Lu creating the radio-immunoconjugate (RIC) 177Lu-DOTA-HH1 (177Lu-HH1, trade name Betalutin). The present toxicity study was performed prior to initiation of clinical studieswith 177Lu-HH1. Methodology/Principal Findings Nude mice with or without tumor xenografts were treated with 50 to 1000 MBq/kg 177Lu- HH1 and followed for clinical signs of toxicity up to ten months. Acute, life threatening bone marrow toxicity was observed in animals receiving 800 and 1000 MBq/kg 177Lu-HH1. Significant changes in serum concentrations of liver enzymes were evident for treatment with 1000 MBq/kg 177Lu-HH1. Lymphoid depletion, liver necrosis and atrophy, and interstitial cell hyperplasia of the ovaries were also observed for mice in this dose group. Conclusions/Significance 177Lu-DOTA-HH1 was well tolerated at dosages about 10 times above those considered relevant for radioimmunotherapy in patients with B-cell derived malignancies.The toxicity profile was as expected for RICs. Our experimental results have paved the way for clinical evaluation of 177Lu-HH1 in NHL patients.

[1]  R. Herrmann,et al.  Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas , 2013, The Journal of Nuclear Medicine.

[2]  M. Lassmann,et al.  Biodistribution and Dosimetry of 177Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma , 2013, Current radiopharmaceuticals.

[3]  L. Królicki,et al.  Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  J. Turner,et al.  Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  G. Paganelli,et al.  Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC. , 2009, Cancer biotherapy & radiopharmaceuticals.

[6]  Marion de Jong,et al.  Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  R. Herrmann,et al.  Radioimmunotherapy (RIT) with 177 Lutetium-DOTA-Rituximab (177LU-D- R): A Phase I/II - Study in 30 Patients with Relapsing Follicular, Mantle Cell and Other Indolent B-Cell Lymphomas , 2008 .

[8]  A. Türler,et al.  Production of 177Lu at the new research reactor FRM-II: Irradiation yield of 176Lu(n,gamma)177Lu. , 2008, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[9]  Shankar Vallabhajosula,et al.  Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Goldenberg,et al.  177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo. , 2005, Nuclear medicine and biology.

[11]  O. Nilsson,et al.  Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer. , 2003, Cancer biotherapy & radiopharmaceuticals.

[12]  B. Autran,et al.  The SCID mouse mutant: definition and potential use as a model for immune and hematological disorders. , 1997, Hematology and cell therapy.

[13]  M. Kaminski,et al.  Intratumoral microdistribution of [131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy. , 1997, Nuclear medicine and biology.

[14]  M. Juweid,et al.  Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22 , 1997, Cancer Immunology, Immunotherapy.

[15]  I. Bernstein,et al.  Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. , 1994, Blood.

[16]  I. Bernstein,et al.  Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. , 1993, The New England journal of medicine.

[17]  M. Kaminski,et al.  Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. , 1992, Cancer research.

[18]  M. Kaminski,et al.  Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Schlom,et al.  Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate. , 1991, Cancer research.

[20]  R. A. Phillips,et al.  The scid mutation in mice causes a general defect in DNA repair , 1990, Nature.

[21]  I. Bernstein,et al.  Imaging and treatment of B-cell lymphoma. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  D. Goldenberg,et al.  Biological considerations for radioimmunotherapy. , 1990, Cancer research.

[23]  A. Farr,et al.  Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. , 1989, Cancer research.

[24]  J. Eary,et al.  Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Smeland,et al.  Characterization of Two Murine Monoclonal Antibodies Reactive with Human B Cells , 1985, Scandinavian journal of immunology.

[26]  E. Murphy Hyperplastic and early neoplastic changes in the ovaries of mice after genic deletion of germ cells. , 1972, Journal of the National Cancer Institute.

[27]  R. Larsen,et al.  Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. , 2013, Anticancer research.

[28]  Ulrich Mohr,et al.  Pathobiology of the aging mouse , 1996 .

[29]  P. Bunn,et al.  Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. , 1986, Methods in enzymology.